Vertaling van "effects of drugs " (Frans → Nederlands) :

Commenté des Médicaments 34 , Farmacotherapeutisch Kompas 35 , British National Formulary 36 , Martindale 37 , Meyler’s Side Effects of Drugs 38 , Geriatric Dosage Handbook 39 , Managing Clinically Important Drug Interactions 40 , Drug Information AHFS 41 .
Gecommentarieerd Geneesmiddelenrepertorium 34 , Farmacotherapeutisch Kompas 35 , British National Formulary 36 , Martindale 37 , Meyler’s Side Effects of Drugs 38 , Geriatric Dosage Handbook 39 , Managing Clinically Important Drug Interactions 40 , Drug Information AHFS 41 .

348, 529-537 (2003) W.E. Evans et H.L. McLeod: Pharmacogenomics - Drug disposition, drug targets and side effects.
348, 529-537 (2003) W.E. Evans en H.L. McLeod: Pharmacogenomics - Drug disposition, drug targets and side effects.

INHALANTS M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, -0,7 5,4 48.607.976 2,8 NON-STEROIDS C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS 16,7 29,3 48.458.787 23,2 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY 4,8 10,5 47.845.796 8,1 VASCULAR EFFECTS L02B HORMONE ANTAGONISTS AND RELATED AGENTS 18,1 16,3 40.001.905 12,5 C01D VASODILATORS USED IN CARDIAC DISEASES -5,3 -0,3 37.257.508 -1,4 B02B VITAMIN K AND OTHER HEMOSTATICS x x 35.730.154 x N06D ANTI-DEMENTIA DRUGS 12,9 12,5 30.096.154 10,2 L02A HORMONES AND RELATED AGENTS -2,3 1,4 29.043.416 -0,3 N04B DOPAMINERGIC AGENTS 11,0 11,6 27.632.755 9,9 L01X OTHER ANTINEOPLASTIC AGENTS 11,6 23,7 26.993.829 15,7
M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, -0,7 5,4 48.607.976 2,8 NON-STEROIDS C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS 16,7 29,3 48.458.787 23,2 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY 4,8 10,5 47.845.796 8,1 VASCULAR EFFECTS L02B HORMONE ANTAGONISTS AND RELATED AGENTS 18,1 16,3 40.001.905 12,5 C01D VASODILATORS USED IN CARDIAC DISEASES -5,3 -0,3 37.257.508 -1,4 B02B VITAMIN K AND OTHER HEMOSTATICS x x 35.730.154 x N06D ANTI-DEMENTIA DRUGS 12,9 12,5 30.096.154 10,2 L02A HORMONES AND RELATED AGENTS -2,3 1,4 29.043.416 -0,3 N04B DOPAMINERGIC AGENTS 11,0 11,6 27.632.755 9,9 L01X OTHER ANTINEOPLASTIC AGENTS 11,6 23,7 26.993.829 15,7

Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs.
Extrapyramidal motor side-effects of first- and secondgeneration antipsychotic drugs.

Gauthier K, Bai A, Perras C et al ; Canadian Agency for Drugs and Technologies in Health. Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis : clinical effectiveness and harms.
postmenopausal osteoporosis : clinical effectiveness and harms.

42. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of the inhibitors of the rennin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.
41. Fored M, Ejerblad E, Lindblad P et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345:1801-8.

effectiveness of a public health model for local drug policy.
circuit: genesis and effectiveness of a public health model for local drug policy.

D'autres sources mentionnent qu'outre le sulindac, le diclofénac présente aussi un risque important d'hépatotoxicité [Journal of Hepatology, 29, 135- 141 (1998); Meyler's Side Effects of Drugs, 14 ème éd.].
Andere bronnen vermelden naast sulindac ook voor diclofenac een belangrijk risico van hepatotoxiciteit [Journal of Hepatology 29, 135-141 (1998); Meyler’s Side Effects of Drugs, 14 de editie].

Costa L.G., Steardo L. et Cuomo V. Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: experimental and clinical aspects.
Costa L.G., Steardo L. en Cuomo V. Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: experimental and clinical aspects.

D’après Meyler’s Side Effects of Drugs et Martindale, toutes les héparines, y compris les héparines de bas poids moléculaire, peuvent provoquer dans de rares cas une hyperkaliémie, surtout lorsque le traitement dépasse les 7 jours; celle-ci peut être cliniquement importante, a fortiori en présence d’autres facteurs de risque.
Volgens Meyler’s Side Effects of Drugs en Martindale kunnen alle heparines, met inbegrip van de heparines met laag moleculair gewicht, in zeldzame gevallen hyperkaliëmie veroorzaken, vooral bij behandeling gedurende meer dan 7 dagen, en kan deze zeker in aanwezigheid van andere risicofactoren klinisch belangrijk zijn.